Leerink Partners Remains Sidelined on Myriad Genetics (MYGN) - PT to $41
Tweet Send to a Friend
Leerink Partners maintained a Market Perform rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $41.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
